Skip to main content
Top
Published in: Supportive Care in Cancer 12/2007

01-12-2007 | Original Article

Symptom and medication profiles among cancer patients attending a palliative care clinic

Authors: Rachel P. Riechelmann, Monika K. Krzyzanowska, Aoife O’Carroll, Camilla Zimmermann

Published in: Supportive Care in Cancer | Issue 12/2007

Login to get access

Abstract

Background

Patients with advanced cancer frequently experience distressful symptoms and receive numerous medications. We describe the symptomatology and medication profile of ambulatory cancer patients receiving exclusively supportive care at the Princess Margaret Hospital.

Materials and methods

This was a retrospective, cross-sectional study. We reviewed the charts of consecutive adult cancer patients attending palliative care clinics and who were no longer receiving cancer-directed therapy. From the medical records, we collected information about self-reported symptoms [screened for with the numerical Edmonton symptom assessment system (ESAS) scale; range, 0–10, with 10=worst symptom] and medication profiles. Summary statistics were used to describe the results.

Results

Two hundred fifty five patients met the inclusion criteria. The most frequent self-reported symptoms of any severity were fatigue (77%), pain (75%), and lack of appetite (66%). These were also the most severe symptoms: fatigue (median ESAS score=7), pain (median ESAS=5), and lack of appetite (median ESAS=5). The median number of medications per patient after consultation in the palliative care service was 6, and the most common classes of drugs prescribed were opioids (67%), laxatives/stool softeners (54%), corticosteroids (41%), and acetaminophen (41%). Palliative care physicians made at least one medication change in 75% of the patients, with the most frequent change being the addition of new medication(s); dexamethasone was the most commonly added individual drug (18% of the patients).

Conclusion

Among patients with advanced cancer not receiving antineoplastic therapy, the most frequent and severe symptoms were fatigue, pain, and lack of appetite. The medication profile represented drugs that could both alleviate and contribute to these symptoms. Audit of patient symptoms and medication prescription in palliative care may inform clinical practice and help the development of research specific to patient symptoms.
Literature
1.
go back to reference Walsh D, Donnelly S, Rybicki L (2000) The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients. Support Care Cancer 8:175–179PubMedCrossRef Walsh D, Donnelly S, Rybicki L (2000) The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients. Support Care Cancer 8:175–179PubMedCrossRef
2.
go back to reference Mancini I, Lossignol D, Obiols M et al (2002) Supportive and palliative care: experience at the Institut Jules Bordet. Support Care Cancer 10:3–7PubMedCrossRef Mancini I, Lossignol D, Obiols M et al (2002) Supportive and palliative care: experience at the Institut Jules Bordet. Support Care Cancer 10:3–7PubMedCrossRef
3.
go back to reference Elsayem A, Swint K, Fisch MJ et al (2004) Palliative care inpatient service in a comprehensive cancer center: clinical and financial outcomes. J Clin Oncol 22:2008–2014PubMedCrossRef Elsayem A, Swint K, Fisch MJ et al (2004) Palliative care inpatient service in a comprehensive cancer center: clinical and financial outcomes. J Clin Oncol 22:2008–2014PubMedCrossRef
4.
go back to reference Riechelmann RP, Tannock IF, Wang L, Krzyzanowska MK (2006) Drug interactions in ambulatory cancer patients receiving cancer-therapy. Proc Am Soc Clin Oncol volume 24: abstract # 6129 Riechelmann RP, Tannock IF, Wang L, Krzyzanowska MK (2006) Drug interactions in ambulatory cancer patients receiving cancer-therapy. Proc Am Soc Clin Oncol volume 24: abstract # 6129
5.
go back to reference Riechelmann RP, Moreira F, Smaletz O et al (2005) Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol 56(3):286–290PubMedCrossRef Riechelmann RP, Moreira F, Smaletz O et al (2005) Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol 56(3):286–290PubMedCrossRef
6.
go back to reference Donnelly S, Walsh D, Rybicki L (1995) The symptoms of advanced cancer: identification of clinical and research priorities by assessment of prevalence and severity. J Palliat Care 11:27–32PubMed Donnelly S, Walsh D, Rybicki L (1995) The symptoms of advanced cancer: identification of clinical and research priorities by assessment of prevalence and severity. J Palliat Care 11:27–32PubMed
7.
go back to reference Jenkins CA, Schulz M, Hanson J et al (2000) Demographic, symptom, and medication profiles of cancer patients seen by a palliative care consult team in a tertiary referral hospital. J Pain Symptom Manage 19:174–184PubMedCrossRef Jenkins CA, Schulz M, Hanson J et al (2000) Demographic, symptom, and medication profiles of cancer patients seen by a palliative care consult team in a tertiary referral hospital. J Pain Symptom Manage 19:174–184PubMedCrossRef
8.
go back to reference Stromgren AS, Sjogren P, Goldschmidt D et al (2006) Symptom priority and course of symptomatology in specialized palliative care. J Pain Symptom Manage 31:199–206PubMedCrossRef Stromgren AS, Sjogren P, Goldschmidt D et al (2006) Symptom priority and course of symptomatology in specialized palliative care. J Pain Symptom Manage 31:199–206PubMedCrossRef
9.
go back to reference Stromgren AS, Sjogren P, Goldschmidt D et al (2005) A longitudinal study of palliative care: patient-evaluated outcome and impact of attrition. Cancer 103:1747–1755PubMedCrossRef Stromgren AS, Sjogren P, Goldschmidt D et al (2005) A longitudinal study of palliative care: patient-evaluated outcome and impact of attrition. Cancer 103:1747–1755PubMedCrossRef
10.
go back to reference Stromgren AS, Goldschmidt D, Groenvold M et al (2002) Self-assessment in cancer patients referred to palliative care: a study of feasibility and symptom epidemiology. Cancer 94:512–520PubMedCrossRef Stromgren AS, Goldschmidt D, Groenvold M et al (2002) Self-assessment in cancer patients referred to palliative care: a study of feasibility and symptom epidemiology. Cancer 94:512–520PubMedCrossRef
11.
go back to reference Nauck F, Ostgathe C, Klaschik E et al (2004) Drugs in palliative care: results from a representative survey in Germany. Palliat Med 18:100–107PubMedCrossRef Nauck F, Ostgathe C, Klaschik E et al (2004) Drugs in palliative care: results from a representative survey in Germany. Palliat Med 18:100–107PubMedCrossRef
12.
go back to reference Twycross RG, Bergl S, John S et al (1994) Monitoring drug use in palliative care. Palliat Med 8:137–143PubMed Twycross RG, Bergl S, John S et al (1994) Monitoring drug use in palliative care. Palliat Med 8:137–143PubMed
13.
go back to reference Koh NY, Koo WH (2002) Polypharmacy in palliative care: can it be reduced? Singap Med J 43:279–283 Koh NY, Koo WH (2002) Polypharmacy in palliative care: can it be reduced? Singap Med J 43:279–283
14.
go back to reference Mercadante S, Fulfaro F, Casuccio A (2001) Pattern of drug use by advanced cancer patients followed at home. J Palliat Care 17:37–40PubMed Mercadante S, Fulfaro F, Casuccio A (2001) Pattern of drug use by advanced cancer patients followed at home. J Palliat Care 17:37–40PubMed
15.
go back to reference Curtis EB, Walsh TD (1993) Prescribing practices of a palliative care service. J Pain Symptom Manage 8:312–316PubMedCrossRef Curtis EB, Walsh TD (1993) Prescribing practices of a palliative care service. J Pain Symptom Manage 8:312–316PubMedCrossRef
16.
go back to reference Zimmermann C, Seccareccia D, Clarke A et al (2006) Bringing palliative care to a Canadian cancer center: the palliative care program at Princess Margaret Hospital. Support Care Cancer 14:982–987PubMedCrossRef Zimmermann C, Seccareccia D, Clarke A et al (2006) Bringing palliative care to a Canadian cancer center: the palliative care program at Princess Margaret Hospital. Support Care Cancer 14:982–987PubMedCrossRef
17.
go back to reference Bruera E, Kuehn N, Miller MJ et al (1991) The Edmonton symptom assessment system (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7:6–9PubMed Bruera E, Kuehn N, Miller MJ et al (1991) The Edmonton symptom assessment system (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7:6–9PubMed
18.
go back to reference Bernhard J, Cella DF, Coates AS et al (1998) Missing quality of life data in cancer clinical trials: serious problems and challenges. Stat Med 17:517–532PubMedCrossRef Bernhard J, Cella DF, Coates AS et al (1998) Missing quality of life data in cancer clinical trials: serious problems and challenges. Stat Med 17:517–532PubMedCrossRef
19.
go back to reference Drummond SH, Peterson GM, Galloway JG et al (1996) National survey of drug use in palliative care. Palliat Med 10:119–124PubMed Drummond SH, Peterson GM, Galloway JG et al (1996) National survey of drug use in palliative care. Palliat Med 10:119–124PubMed
20.
go back to reference Prue G, Rankin J, Allen J et al (2006) Cancer-related fatigue: a critical appraisal. Eur J Cancer 42:846–863PubMedCrossRef Prue G, Rankin J, Allen J et al (2006) Cancer-related fatigue: a critical appraisal. Eur J Cancer 42:846–863PubMedCrossRef
21.
go back to reference Lundstrom SH, Furst CJ (2006) The use of corticosteroids in Swedish palliative care. Acta Oncol 45:430–437PubMedCrossRef Lundstrom SH, Furst CJ (2006) The use of corticosteroids in Swedish palliative care. Acta Oncol 45:430–437PubMedCrossRef
22.
go back to reference Ashbury FD, Madlensky L, Raich P et al (2003) Antidepressant prescribing in community cancer care. Support Care Cancer 11:278–285PubMed Ashbury FD, Madlensky L, Raich P et al (2003) Antidepressant prescribing in community cancer care. Support Care Cancer 11:278–285PubMed
Metadata
Title
Symptom and medication profiles among cancer patients attending a palliative care clinic
Authors
Rachel P. Riechelmann
Monika K. Krzyzanowska
Aoife O’Carroll
Camilla Zimmermann
Publication date
01-12-2007
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 12/2007
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-007-0253-8

Other articles of this Issue 12/2007

Supportive Care in Cancer 12/2007 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine